CA3064973A1 - Dosing of vibegron for treatment of overactive bladder - Google Patents

Dosing of vibegron for treatment of overactive bladder Download PDF

Info

Publication number
CA3064973A1
CA3064973A1 CA3064973A CA3064973A CA3064973A1 CA 3064973 A1 CA3064973 A1 CA 3064973A1 CA 3064973 A CA3064973 A CA 3064973A CA 3064973 A CA3064973 A CA 3064973A CA 3064973 A1 CA3064973 A1 CA 3064973A1
Authority
CA
Canada
Prior art keywords
vibegron
dosage
per day
weeks
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3064973A
Other languages
English (en)
French (fr)
Inventor
Stephen C. PISCITELLI
Paul Mudd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urovant Sciences GmbH
Original Assignee
Urovant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urovant Sciences GmbH filed Critical Urovant Sciences GmbH
Publication of CA3064973A1 publication Critical patent/CA3064973A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3064973A 2017-06-06 2018-06-06 Dosing of vibegron for treatment of overactive bladder Pending CA3064973A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762516013P 2017-06-06 2017-06-06
US62/516,013 2017-06-06
US201862635310P 2018-02-26 2018-02-26
US62/635,310 2018-02-26
US201862637949P 2018-03-02 2018-03-02
US62/637,949 2018-03-02
PCT/IB2018/054070 WO2018224990A1 (en) 2017-06-06 2018-06-06 Dosing of vibegron for treatment of overactive bladder

Publications (1)

Publication Number Publication Date
CA3064973A1 true CA3064973A1 (en) 2018-12-13

Family

ID=62815098

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3064973A Pending CA3064973A1 (en) 2017-06-06 2018-06-06 Dosing of vibegron for treatment of overactive bladder

Country Status (9)

Country Link
US (2) US20210077496A1 (enExample)
EP (1) EP3634488A1 (enExample)
JP (2) JP7670461B2 (enExample)
KR (2) KR20200012939A (enExample)
CN (1) CN110869053A (enExample)
AU (2) AU2018282105A1 (enExample)
CA (1) CA3064973A1 (enExample)
MX (1) MX2023000187A (enExample)
WO (1) WO2018224990A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250099259A (ko) 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
CA3085745A1 (en) * 2017-12-21 2019-06-27 Kyorin Pharmaceutical Co., Ltd. An agent for treating nocturnal pollakiuria
MX2021003980A (es) * 2018-12-05 2021-07-21 Urovant Sciences Gmbh Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva.
JP2022524576A (ja) * 2019-03-18 2022-05-09 ウロバント サイエンシズ ゲーエムベーハー 過活動膀胱を処置するためのビベグロンの使用
AU2021405413A1 (en) * 2020-12-22 2023-07-06 Urovant Sciences Gmbh Methods of monitoring digoxin with concomitant use of vibegron to treat overactive bladder
KR20250051257A (ko) 2023-10-10 2025-04-17 (주)케이아트휀스 지주파이프 롤포밍 장치

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
CN102638987A (zh) * 2009-10-07 2012-08-15 默沙东公司 使用β3肾上腺素能受体激动剂和抗毒蕈碱药剂的组合疗法
US20150087832A1 (en) 2011-10-27 2015-03-26 Merck Sharp & Dohme, Corp. Process for making beta 3 agonists and intermediates
US9809536B2 (en) 2011-10-27 2017-11-07 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
ME03506B (me) 2013-03-15 2020-04-20 Merck Sharp & Dohme Postupak za pripremu beta 3 agonista i međuproizvoda
EP3463312A4 (en) * 2016-06-03 2020-02-05 Velicept Therapeutics, Inc. DOSAGE DIAGRAMS FOR BETA-3 ADRENERGIC RECEPTOR AGONISTS AND ANTI-MUSCARIN AGENTS FOR THE TREATMENT AND PREVENTION OF LOWER URINARY SYMPTOMS AND VESICAL HYPERACTIVITY

Also Published As

Publication number Publication date
US20230218624A1 (en) 2023-07-13
KR20200012939A (ko) 2020-02-05
KR20250095747A (ko) 2025-06-26
US20210077496A1 (en) 2021-03-18
EP3634488A1 (en) 2020-04-15
JP2020523334A (ja) 2020-08-06
AU2018282105A1 (en) 2019-12-12
AU2024204108A1 (en) 2024-07-04
CN110869053A (zh) 2020-03-06
JP7670461B2 (ja) 2025-04-30
WO2018224990A1 (en) 2018-12-13
JP2023058635A (ja) 2023-04-25
MX2023000187A (es) 2023-02-09

Similar Documents

Publication Publication Date Title
US20230218624A1 (en) Dosing of vibegron for treatment of overactive bladder
AU2024204591A1 (en) Use of vibegron to treat overactive bladder
AU2019393372B2 (en) Vibegron for the treatment of overactive bladder symptoms
EP2059245A1 (en) Bifeprunox doses for treating schizophrenia
CA3098536A1 (en) Use of vibegron to treat pain associated with irritable bowel syndrome
TWI488658B (zh) 溶出性之改善方法
HK40114255A (en) Use of vibegron to treat overactive bladder
EA045454B1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
AU2023292263A1 (en) Phloroglucinol formulations and methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220824

EEER Examination request

Effective date: 20220824

EEER Examination request

Effective date: 20220824

EEER Examination request

Effective date: 20220824

EEER Examination request

Effective date: 20220824

EEER Examination request

Effective date: 20220824